Educational only — not medical advice. We explain the research so you can decide with clear eyes.

About this site
Peptide Atlas
← All compounds
EmergingNootropic / anxiolytic

Selank

Selank is a lab-made version of a natural immune peptide that Russian researchers have studied for decades as a calming, anti-anxiety compound that doesn't sedate or cause dependence the way typical anxiety drugs do.

Mood & stressFocus & memoryGut healthImmune support
Not FDA-approvedNo confirmed human dose in these studiesMost human data comes from Russia onlyLong-term safety not establishedNeeds medical supervision if combined with anxiety medication

Selank was created in Russia in the 1990s by extending tuftsin, a small peptide your immune system already makes, so it would last longer in the body once it's given. It has been used as an approved anxiety treatment in Russia for years, but it has never gone through FDA review and isn't approved in the US or Europe. Most of what's known comes from a handful of Russian clinical trials involving a few hundred patients total, backed up by a much larger stack of animal and lab studies that dig into how it works and what else it might do.

How strong is the evidence?

Real human trials exist, but they're small (30 to 70 patients each), were run in Russia, mostly compare Selank against older benzodiazepine drugs rather than a placebo, and aren't reported with the level of detail expected in modern Western trials. One well-designed human study used brain scans (fMRI) in 52 healthy volunteers with a placebo arm, which is the strongest human evidence on file. Everything else, dozens of studies, is in rats, mice, or cells in a dish, mapping out how Selank works and testing it for stress, memory, gut health, and immune effects. That mix puts Selank in the 'limited human evidence' category: promising and consistent signals, but not proof at the level of an approved modern medicine.

Uses

What people use it for

Anxiety and stress-related disorders

Some human data

Russian clinical trials have tested Selank in people with generalized anxiety disorder, phobic-anxiety conditions, somatoform disorders, and neurasthenia (a burnout-like condition of chronic fatigue and irritability), comparing it head-to-head with standard anti-anxiety drugs.

Add-on to prescription anxiety medication

Some human data

In one trial, adding Selank to a benzodiazepine (phenazepam) got patients feeling better sooner and cut down on the drug's side effects like grogginess and memory problems.

Memory and mental sharpness support

Animal / lab

A long line of animal studies shows Selank helps rats learn faster and remember longer, especially in animals that started out as slow learners.

Stress resilience and recovery

Animal / lab

In animals under repeated stress, Selank protected the gut lining, calmed stress hormone levels, and helped organs bounce back faster.

Withdrawal support for opioids or alcohol

Animal / lab

In rodent models, Selank eased physical signs of morphine withdrawal and blunted alcohol's stimulant-like effects on behavior.

Potential benefits

What it may help with

  • Eases anxiety symptoms

    Some human data

    In small Russian trials, Selank reduced anxiety scores about as well as standard benzodiazepine drugs (phenazepam, medazepam), without the same drowsiness or dependence risk.

  • Works well alongside standard anxiety medication

    Some human data

    Adding Selank to phenazepam treatment sped up symptom relief and cut down on the medication's side effects, including sedation, memory problems, and low sex drive.

    Studies:26356395
  • Changes brain activity patterns tied to anxiety

    Some human data

    A placebo-controlled brain-scan study in 52 healthy people found Selank altered communication between the amygdala (the brain's alarm center) and areas involved in processing emotional information, within 20 minutes of dosing.

    Studies:32342318
  • Supports learning and memory

    Animal / lab

    Across many rat studies, Selank sped up learning, protected memory from alcohol-related damage, and restored cognitive function after early-life brain injury.

  • Helps the body handle chronic stress

    Animal / lab

    In stressed rats, Selank protected the gut lining and healthy gut bacteria, calmed stress hormone (corticosterone) levels, and preserved gastric blood flow.

  • May ease drug and alcohol withdrawal

    Animal / lab

    Selank reduced physical signs of morphine withdrawal in rats and blocked alcohol-induced hyperactivity and sensitization in mice.

  • Calms the brain through GABA and the body's own opioid-like chemical

    Theory

    Lab and animal studies suggest Selank boosts how well GABA (the brain's main calming signal) works, and separately protects enkephalin, a natural calming and pain-easing chemical, from being broken down too quickly.

  • May help balance immune system activity

    Animal / lab

    As a peptide built from an immune signal (tuftsin), Selank changes the activity of inflammation-related genes and cytokines in animal and lab studies.

What to watch for

Side effects & risks

  • Mild

    Well tolerated in the trials so far

    Across the human trials on file, Selank didn't show the sedation, memory fog, or dependence issues seen with benzodiazepine anxiety drugs, and no serious adverse events were reported.

  • Mild

    May work less well, or slightly worsen anxiety, if taken repeatedly with no stress present

    In one rat study, giving a course of Selank when there was no stressor around actually nudged anxiety indicators in the wrong direction, though it worked well again once stress was reintroduced. It's not clear if this happens in people.

Dosing

Dosing — what studies used

There's no human dose here that's been clearly spelled out or vetted for self-directed use. Animal studies consistently used 0.3 mg/kg (delivered straight into the abdominal cavity, not something a person can replicate at home) as the go-to anxiety and memory dose. The human clinical trials in Russia gave Selank as a daily course for roughly two weeks, but the published abstracts don't state the actual milligram amount patients took. Any specific human milligram dose you see quoted elsewhere isn't backed by the studies reviewed here.

How it's taken:Intraperitoneal injection (animal studies)Intranasal (tested in animals; also the standard form used in Russian commercial products)Not specified in the human trial abstracts on file

Anxiety and memory studies in rats and mice

Animal study

0.3 mg/kg body weight (300 mcg/kg)

Once daily, as a single dose or repeated over several days · Single dose up to about 7 days · Intraperitoneal injection

This is the most common research dose used across dozens of animal studies for anxiety, memory, and withdrawal effects.

Dose-ranging chronic stress studies in rats

Animal study

80 to 1000 mcg/kg body weight

Once daily, about 15 minutes before each stress exposure · Days to weeks, depending on the stress protocol · Intraperitoneal injection

Researchers tested a range of doses; protective effects showed up across the whole range, with doses around 300 mcg/kg often standing out.

Route comparison study in mice

Animal study

300 mcg/kg per day

Once daily for 5 days · 5 days · Intranasal, compared head-to-head with intraperitoneal injection

Both routes worked, but affected brain receptors somewhat differently, suggesting how Selank is given changes how it acts.

Human anxiety trials

Human trial

Not stated in the published abstracts

Daily · About 14 days in one immune-focused study; other anxiety trials described a treatment 'course' without giving an exact length · Not specified in these abstracts (commercial Russian products are typically a nasal spray)

None of the human studies reviewed here reported the milligram dose patients actually received. Don't treat animal doses as a stand-in for a human dose.

Selank itself is thought to be broken down quickly by the body, and small leftover pieces (like the fragment Gly-Pro) may stick around and keep contributing to its effects. None of the papers here gives an exact half-life figure for humans.

These figures describe what researchers used in studies. They are not a recommendation or a prescription.

Mechanism

How it works

Selank is built from tuftsin, a tiny signaling molecule your immune system already makes, tweaked so it survives longer once it's in the body. Researchers think it calms the brain two main ways. First, it seems to help GABA work better, GABA is the brain's main 'settle down' chemical, and it's the same target that standard anti-anxiety pills like Valium and Xanax hit, just less selectively and with more side effects. Second, it protects enkephalin, one of the body's own natural calming, pain-easing chemicals, from being broken down too fast, so its effects last longer. Animal studies also show Selank shifts levels of serotonin and dopamine, brain chemicals tied to mood and motivation, and raises BDNF, a protein that helps brain cells form new connections, which may explain its memory-boosting effects. Outside the brain, it dials down inflammatory signals (cytokines), which likely explains why it helps the gut and other organs recover faster during chronic stress.

Who should avoid it

  • Pregnant or breastfeeding women (no safety data exists for this group)
  • Children and teenagers (all trials were done in adults)
  • Anyone with a bleeding disorder or on blood-thinning medication, until a doctor weighs in
  • People with autoimmune disease or on immune-suppressing drugs, since Selank is built from an immune signal and shifts immune activity
  • Anyone looking to replace medically supervised anxiety treatment with Selank instead of using it alongside proper care

Interactions to know

  • Benzodiazepines (diazepam, phenazepam, medazepam): studied together in both animals and people, and the combination generally worked well, sometimes reducing the sedation and memory fog these drugs cause, but this pairing should only be tried with a doctor involved.
  • Opioid painkillers: animal research suggests part of Selank's effect runs through the body's opioid system, so combining it with opioid medications could change how either one behaves.
  • Alcohol: animal studies show Selank blunts some of alcohol's stimulant-like effects on behavior, so how it interacts with drinking in people isn't predictable.
  • Antipsychotics like olanzapine: lab studies show Selank changes how these drugs affect brain gene activity, an interaction that isn't well understood in people.
  • Blood-thinning medication: older research on related peptides looked at effects on blood clotting, so anyone on anticoagulants should check with a doctor before combining them with Selank.

The papers that matter most

Key studies

  1. 2008Human trial (comparative, 62 patients)PMID 18454096

    Selank worked about as well as the benzodiazepine medazepam for anxiety and neurasthenia, with added antifatigue and mild stimulant-like effects.

    Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia

  2. 2015Human trial (comparative, 70 patients)PMID 26356395

    Adding Selank to phenazepam treatment brought relief faster and reduced the medication's side effects like sedation and memory problems.

    Optimization of the treatment of anxiety disorders with selank

  3. 2014Human trial (comparative, 60 patients)PMID 25176261

    Selank showed a clear anti-anxiety effect that lasted about a week after the last dose, plus a mild memory-supporting effect.

    A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders

  4. 2020Human trial (placebo-controlled fMRI, 52 healthy volunteers)PMID 32342318

    A single dose changed brain connectivity between the amygdala and emotion-processing regions within 20 minutes, real evidence Selank acts on anxiety-related brain circuits in people.

    Functional Connectomic Approach to Studying Selank and Semax Effects

  5. 2001Human/lab mechanism studyPMID 11550013

    Selank blocks the enzymes that break down enkephalin, the body's own calming chemical, which may explain why it works without classic anti-anxiety drug side effects.

    The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity

  6. 2018Lab mechanism studyPMID 30255741

    Selank acts as a positive allosteric modulator of GABA receptors, the same general target as benzodiazepine anxiety drugs, but through a distinct binding site.

    Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity

Bottom line

Selank has a real, decades-long human track record for anxiety in Russia and a mechanism that makes biological sense, but it hasn't been tested to modern Western clinical trial standards, and the exact human dose was never spelled out in the studies reviewed here. Treat it as an interesting, moderately promising option, not a proven substitute for medically supervised anxiety treatment.

Research papers

Studies we have on file for Selank. Tap a title to open it on PubMed. Labels like “animal” or “human trial” are rough guides.

40 papers

Animal study: 25Other: 8Human (observational): 6Lab / cells: 1
2026Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Otherin vitroPMID 41490200

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators, and neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity. Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

2017Current medicinal chemistry

Tuftsin - Properties and Analogs.

Human (observational)humanPMID 28745220

Immunomodulation is one of the significant therapeutic strategies. It includes both stimulation and suppression of the immune system by a variety of substances called immunomodulators, designed to regulate the immune response of the organism against infections of varying etiology. An example of such a substance is tuftsin (TKPA) 3 (Fig. (1)). In this paper were included tuftsin derivatives, which were described over the years, their together with biological activity and clinical potential. We reviewed a bibliographic database to gather all the important information about the tuftsin peptide. We have delineated the significant information on the activity of the tetrapeptide itself and its derivatives. Analogs were divided because of their anti-tumor, anti-inflammatory, antimicrobial and anti-viral activity. This paper describes eighty-six documents. Thirty-two of them concern on activity of tuftsin in the human organism. The remaining fifty-four describe peptide analogues and their properties, including eleven papers about the tuftsin-based peptides contained in the vaccines, nine papers representing anticancer activity of the tuftsin derivatives, twenty-six about antiinflammatory compounds, and five papers describing the antitumor activity of the tuftsin analogs. The findings of this review confirm the importance of the tuftsin and their derivatives. Most of these substances showed anti-tumor, anti-inflammatory or antibacterial activities. A large amount of the compounds may find use in vaccines. Tuftsin can also be used to prepare fusion proteins in the treatment of cancer and as carriers of many biologically active substances.

2022Bulletin of experimental biology and medicine

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.

Animal studyratPMID 36322304

Activity of a peptide tuftsin analogue Selank was studied in outbred rats using the naloxone-precipitated morphine withdrawal model. Single intraperitoneal injection of Selank in an anxiolytic dose of 0.3 mg/kg reduced the total index of morphine withdrawal syndrome by 39.6%, significantly (&#x440;<0.0001) attenuated convulsive reactions, ptosis, and posture disorders, and 9-fold increased the tactile sensitivity threshold in morphine-dependent rats in comparison with the group of active control; at the same time, Selank was slightly inferior to diazepam in a dose of 2 mg/kg by pharmacological activity (the decrease in total index of morphine withdrawal syndrome by 49.3% and 13-fold increase in sensitivity threshold). Thus, Selank, like diazepam, weakens the aversive signs of morphine withdrawal in rats with opiate dependence.

2019Bulletin of experimental biology and medicine

Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.

Animal studyratPMID 31243679

We studied the effects of Selank on morphological parameters of the liver in Wistar male rats subjected to chronic foot-shock stress. Selank was injected intraperitoneally in doses of 100, 300 and 1000 &#x3bc;g/kg 15 min before each stress session. Morphological and morphometrical analysis showed that chronic foot-shock stress induced hydropic degeneration of hepatocytes, an increase of the nucleus/cytoplasm ratio due to an increase in the area of nuclei and reduction of the cytoplasm area, the appearance of focal necroses, and lymphohistiocyte infiltration. Injection of Selank in all doses reduced the intensity of stress-induced degenerative changes. Administration of Selank in doses of 300 and 1000 &#x3bc;g/kg restored the nucleus/cytoplasm ratio in hepatocytes. The maximum stress-limiting effect was attained after administration of 300 &#x3bc;g/kg Selank.

2014Molecular immunology

The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action.

Animal studymousePMID 24291245

Previous studies have shown that synthetic tuftsin analogue Selank and its fragments cause a number of alterations in the expression of certain genes involved in inflammation in mouse spleen. In this work we studied the effect of Selank and its short fragment Gly-Pro on the temporary dynamics of C3, Casp1, Il2rg, and Xcr1 genes expression in mouse spleen after single intraperitoneal injection (100 &#x3bc;g/kg) of peptides using real-time PCR method. We found a significant 3-fold decrease in the C3 mRNA level just 30 min after Selank injection and similar alteration this gene mRNA level after Gly-Pro administration. A wave-like alteration in the Casp1 mRNA level was observed after Selank injection. We found a significant alteration in the mRNA level of the Il2rg gene at early time points after Selank and Gly-Pro administration and an almost equal reduction in the Xcr1 mRNA level 90 min after the administration of Selank and its fragment. Our results showed that, Selank and its short fragment Gly-Pro influence the expression of genes that mediate different types of immune responses, thereby maintaining the balance of the immune system. It should be noted that in most cases, there was a coincidence in the expression profiles of the studied genes after Selank and Gly-Pro administration. This might indicate an active contribution of the dipeptide to the final effect of Selank.

2017Frontiers in pharmacology

GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.

Clinical studies have shown that Selank had an anxiolytic effect comparable to that of classical benzodiazepine drugs, which can enhance the inhibitory effect of GABA by allosteric modulation of GABAA receptors. These data suggest that the molecular mechanism of the effect of Selank may also be related to its ability to affect the performance of the GABAergic system. To test this hypothesis, we studied the changes in expression of 84 genes involved in the functioning of the GABAergic system and in the processes of neurotransmission in the culture of neuroblastoma IMR-32 cells using qPCR method. As test substances, in addition to Selank, we selected the major GABAA receptor ligand, GABA, the atypical antipsychotic, olanzapine, and combinations of these compounds (Selank and GABA; Selank and olanzapine). We found no changes in the mRNA levels of the genes studied under the effect of Selank. The combined effect of GABA and Selank led to nearly complete suppression of changes in expression of genes in which mRNA levels changed under the effect of GABA. When Selank was used in conjunction with olanzapine, the expression alterations of more genes were observed compared with olanzapine alone. The data obtained indicate that Selank has no direct effect on the mRNA levels of the GABAergic system genes in neuroblastoma IMR-32 cells. At the same time, our results partially confirm the hypothesis that the peptide may affect the interaction of GABA with GABAA receptors. Our data also suggest that Selank may enhance the effect of olanzapine on the expression of the genes studied.

2020Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections

Functional Connectomic Approach to Studying Selank and Semax Effects.

Human (observational)humanPMID 32342318

The present study was aimed at the assessment of effects of anxiolytic Selank and nootropic Semax on the whole-brain resting-state functional connectivity (FC) of each of the predefined regions of interest (ROIs) in 52 healthy participants. The ROIs included amygdala (one of the key regions for the regulation of anxiety) and dorsolateral prefrontal cortex (DLPFC; the key region for executive functions, including working memory) in the right and left hemisphere. Resting-state fMRI was carried out three times, namely before, after 5 and 20 min of the injection of either Semax, or Selank, or placebo. Between-group alongwith between-condition differences were revealed in FC between the right amygdala and a region in fusiform, inferior and middle temporal as well as parahippocampal gyri in the right hemisphere. Post hoc analysis allowed us to define both general and specific effects of Selank and Semax on FC between the right amygdala and the right temporal cortex for the first time.

2016Frontiers in pharmacology

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.

Animal studyratPMID 26924987

Clinical studies have shown the similarity of the spectrum of physiological effects of Selank and classical benzodiazepines, such as diazepam and phenazepam. These data suggest that there is a similar basis of their mechanism of action. To test this hypothesis we studied the effect of Selank and GABA on the expression of genes involved in neurotransmission. We analyzed the expression of 84 genes involved in neurotransmission (e.g., major subunit of the GABA receptor, transporters, ion channels, dopamine, and serotonin receptors) in the frontal cortex of rats 1 and 3 h after the administration of Selank or GABA (300 &#x3bc;g/kg) using real-time PCR method. We found significant changes in the expression of 45 genes 1 h after the administration of the compounds. Three hours after Selank or GABA administration, 22 genes changed their expression. We found positive correlation between the changes in genes expression within 1 h after administration of Selank or GABA. Our results showed that Selank caused a number of alterations in the expression of genes involved in neurotransmission. The data obtained indicate that Selank is characterized by its complex effects on nerve cells, and one of its possible molecular mechanisms is associated with allosteric modulation of the GABAergic system.

2018Protein and peptide letters

Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.

Anxiety and mood disorders are the most abundant mental health problems worldwide. The commonly used in clinical practice anxiolytics are focused on pharmacological modulation of brain GABA receptor system activity. As a rule, their use presents a wide spectrum of clinical issues such as dependence, memory impairment and etc. There is an increasing appreciation of the role of neuropeptides and bioactive lipids in the pathophysiology of mood and anxiety disorders as "mild" agents. Heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) exhibits prolonged anti-anxiety and nootropic effects. In this issue, we tried to find the molecular mechanisms which may underlie Selank antianxiety effects. The main method we used was the radioligand - receptor method of analysis. We also used HPLC (to obtain and ensure reagents and Selank purity) and the methods of brain cells plasmatic membranes isolation and following detection of protein concentration in membrane samples. It was shown that Selank affect the [3H]GABA binding as a positive allosteric modulator. The joint action of Selank and some of benzodiazepines also regulates activity of [3H]GABA binding in specific manner, which is not cumulative and differs from either substance individually. Selank is able to block the modulatory activity of Diazepam and Olanzapine, the location of their and peptide binding sites apparently not the same, but potentially may partially overlaps. Thus, we hypothesized and showed that one of Selank anti-anxiety molecular mechanisms can be associated with subtype selective concentration - dependent allosteric modulation of GABA receptors.

2015Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Optimization of the treatment of anxiety disorders with selank].

Human (observational)humanPMID 26356395

To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders. Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clinically and with HDRS, CGI and Spilberger scales. Tolerability was evaluated using the UKU scale. Stroop test and verbal fluency test were used. Quality of life was assessed with the SF-36. The positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS. The combined treatment decreased the level of undesirable side-effects of phenazepam (attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference and orthostatism) during the course of treatment and after the tranquilizer withdrawal. Taken together, the therapeutic efficacy and reduction of side-effects had a positive impact on the quality-of-life of the patients treated with selank as add-on to phenazepam. The results extend therapeutic possibilities of treatment of anxietyspectrum disorders with the combination of benzodiazepine tranquilizers and selank.

2017Behavioural neurology

Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.

Animal studyratPMID 28280289

It was shown that the anxiolytic effect of Selank is comparable to that of classical benzodiazepine drugs and that the basis of their mechanism of action may be similar. These data suggest that the presence of Selank may change the action of classical benzodiazepine drugs. To test this hypothesis, we evaluated the anxiolytic activity of Selank and diazepam in rats both under conditions of unpredictable chronic mild stress and in its absence, after the individual and combined administration of these compounds using the elevated plus maze test. We found that, even in the absence of chronic stress, the administration of a course of test substances changed anxiety indicators toward their deterioration, but the changes after the administration of a course of Selank were less pronounced. In conditions of chronic stress, anxiety indicator values after the simultaneous use of diazepam and Selank did not differ from the respective values observed before chronic stress exposure. The data obtained indicate that the individual administration of Selank was the most effective in reducing elevated levels of anxiety, induced by the administration of a course of test substances, whereas the combination of diazepam with Selank was the most effective in reducing anxiety in unpredictable chronic mild stress conditions.

2021Current reviews in clinical and experimental pharmacology

The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.

Animal studyratPMID 32621722

It was previously thought that inflammation and an immune response were the only factors capable of causing IL-1&#x3b2;, IL-6 and other cytokine`s production. In recent years data have appeared that stressful effects can also occupy an important place, enhancing production of IL- 1&#x3b2;, IL-6 and other cytokines; the result will be a change in the functional activity of a particular cell element, for example immunocompetent cells with subsequent development of inflammation, or a change in the functional activity of neurons. This experiment is aimed at studying the effect of the Selank glyprolin neuropeptide drug on the level of cytokines in animals under conditions of "social" stress, the results of which indicate the presence of stress-protective activity. White nonlinear rats were used as experimental animals. A model of confrontations between males was chosen to create a "social" stress. The animals were in pairs in a cage which were separated by a septum preventing physical contact but having openings that provide sensory contact. Each day, the septum was removed for 10 minutes leading in an overwhelming majority to agonistic collisions (confrontations). Laboratory animals were divided into 3 groups: a group of intact males, a group of animals that were subjected to stress (sensory contact) for 20 days and a group that received intraperitoneally Selank at a dose of 100 mcg/kg/day under conditions of 20-day stress. The level of cytokines under study was determined by enzyme-linked immunosorbent assay. As a result of the work performed to determine the concentration of pro-inflammatory and anti- inflammatory cytokines, it was found that in the serum of animals exposed to stress, there was a statistically significant increase in the level of IL-1&#x3b2;, IL-6 and TGF-&#x3b2;1 in individuals with both types of behavior. It should be noted that, under the conditions of this stressful impact, there was a tendency to decrease the concentration of IL-4 and increase the level of TNF-&#x3b1; but these indicators were not statistically significant. Evaluation of the effect of Semax on the level of the cytokines in a stress-induced state showed that this neuropeptide causes a decrease in the concentration of IL-1&#x3b2; and IL-6, restoration of the level of IL-4, as well as suppression of the production of TGF-&#x3b2;1 and TNF-&#x3b1; in these conditions. This peptide is able to reduce the concentration of IL-1&#x3b2;, IL-6 and TNF-&#x3b1;, as well as TGF-&#x3b2;1, practically reaching control values, when studying the effect of Selank on the level of cytokines under conditions of " social" stress. There is the need for a detailed study of the role of cytokines in the development of stress-induced changes in order to find optimal correction tools.

2020Bulletin of experimental biology and medicine

Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.

Animal studyratPMID 32651826

We studied the effects of Selank on the condition of the colon wall in Wistar male rats subjected to restraint stress. Selank was injected intraperitoneally in doses of 80, 250, and 750 &#x3bc;g/kg 15 min before stress exposure. In rats subjected to stress, signs of atrophy, inflammatory reaction, and changes in the number and functional activity of mast cells were observed against the background of increased corticosterone level. Selank administration led to a decrease in corticosterone levels, reduced pathomorphological manifestations of stress exposure, and accelerated adaptation. These effects were presumably realized due to multifunctional biological effects of Selank.

2019Bulletin of experimental biology and medicine

State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment.

Animal studyratPMID 31236882

We studied the effects of Selank on intestinal microbiota in Wistar male rats subjected to chronic restraint stress. Selank was injected intraperitoneally in doses of 80, 250 and 750 &#x3bc;g/kg 15 min before stress exposure. Chronic restraint stress led to a decrease in the content of obligate microflora, while the content of opportunistic microorganisms increased. Selank restored intestinal microbiota presumably via central (neurotropic) and peripheral (immunotropic) mechanisms.

2003Neuroscience and behavioral physiology

The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats.

Animal studyratPMID 14552529

The actions of the synthetic heptapeptide preparation Selank on learning and memory processes in rats with initially low levels of learning ability were compared with those in normal rats, using a method based on acquisition of a conditioned active avoidance reflex, with repeated administration of peptide 15 min before the start of training sessions for four days. The effects of Selank (300 microg/kg) were compared with the effects of the nootrope piracetam (400 mg/kg). These experiments showed that Selank significantly activated the learning process in rats with initially poor learning ability, with effects apparent after first dose on training day 1. The effect progressively increased on repeated administration of Selank: the total number of correct solutions increased and the number of errors decreased (p < 0.05). The maximum optimizing activity of Selank on learning in normal rats was seen on day 3 of repeated administration and training, i.e., after formation of the initial consolidation phase. The dynamic features of the development of the activating action of Selank and piracetam were described. Comparison of the results obtained here with data on the anti-anxiety actions of Selank suggested potential for its use in optimizing mnestic functions in conditions of elevated emotional tension.

2008Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova

[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice].

Animal studyratPMID 18661785

A synthetic derivative of the endogenous peptide tuftsin heptapeptide selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) possesses an anxiolytic and psychostimulant effect, and represents a working element of a new peptide drug having completed the third phase of the clinical testing as a selective anxiolytic. The neurobiochemical spectrum of selank action combines mechanisms which are characteristics of antidepressants and psychostimulants: activation of the brain monoaminergic systems, dopamine synthesis and turnover, and modulation of the tyrosine hydroxylase activity. The aim of this study was to investigate the effect of selank in a new model of inherited (genetically-based) symptoms of depression in behavior of inbred WAG/Rij rats in comparison with its effect on situation-provoked symptoms of depression in behavior of BALB/c mice. Outbred Wistar rats constituted control group. Selank in high doses (1000-2000 microg/kg), after repeated injection counteracted symptoms of depression in behavior of WAG/Rij rats (increased immobilization in the forced swimming test and decreased sucrose intake or preference (anhedonia)). Selank in low doses (100 and 300 microg/kg) after single injection reduced the duration of immobility of BALB/c mice in the forced swimming test, but did not exert significant effect after repeated injection or after injection in high doses (600 and 900 microg/kg). Selank did not affect the level of general locomotor activity and anxiety in WAG/Rij rats, and did not exert substantial effect on the behavior of control Wistar rats. The results demonstrate the presence of antidepressant component in the spectrum of neuropsychotrophyc activity of selank and indicate the higher reliability of a new experimental model of depression (the WAG/Rij rats) as compared to the standard forced swimming test for the determination of antidepressant activity of a pharmacological drug.

2011Regulatory peptides

Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank.

Animal studyratPMID 21609736

Previous studies have shown that synthetic tuftsin analogue Selank causes a transcriptomic response in the rat hippocampus and in spleen cells and may participate in the regulation of inflammatory processes in the body. In this work we studied the effect of Selank and two of its fragments on the expression of genes involved in processes of inflammation. We analyzed the expression of 84 genes involved in processes of inflammation (e.g., chemokines, cytokines, and its receptors) in mouse spleen 6 and 24 h after Selank single intraperitoneal injection (100 &#x3bc;g/kg) using real-time PCR method. We found significant changes in the expression of 34 genes involved in inflammation processes. The detailed analysis of quantitative data showed that the Bcl6 gene, which plays a main role in the formation and development of the immune system, exhibited significant changes in its expression levels in response to injection of each of the peptides. Also, we observed expression changes for Bcl6 target and corepressor genes under the influence of Selank and its fragments. Our results showed that Selank and its fragments caused a number of alterations in the expression of genes involved in inflammation. The data obtained confirmed the participation of Selank in the processes of regulation of inflammation in the body. The complex biological effect of Selank may be partially determined by the systematic effect of this peptide on genomic expression.

2017Bulletin of experimental biology and medicine

Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons.

Animal studyratPMID 28361410

Application of anxiolytic drug Selank to hippocampal slices increased the amplitude and discharge rate of spontaneous inhibitory postsynaptic currents in rat hippocampal pyramidal CA1 neurons. In some neurons, Selank-induced up-regulation of spontaneous inhibitory postsynaptic currents was preceded by a transient decrease in this activity. In the examined concentration range (1-8 &#x3bc;M), Selank demonstrated no significant dose-dependence.

2017Bulletin of experimental biology and medicine

Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress.

Animal studyratPMID 28853100

We studied the effect of Selank administered intraperitoneally in doses of 100, 300, and 1000 &#x3bc;g/kg to male Wistar rats 15 min prior to restraint stress on the content of aminotransferases and total protein concentration in blood serum and intensity of free radical oxidation in the liver. Under conditions of acute restraint stress, Selank in doses of 100 and 300 &#x3bc;g/kg decreased catalase and superoxide dismutase activities and malondialdehyde concentration and increased total antioxidant activity in the liver homogenate. Administration of Selank in a dose of 1000 &#x3bc;g/kg reduced the content of aminotransferases in blood serum, decreased superoxide dismutase activity in the liver, and increased total antioxidant activity. Under conditions of chronic stress, Selank in all doses produced similar effects: reduced superoxide dismutase activity and malondialdehyde concentration in the liver tissue and AST activity in the serum. The other parameters remained unchanged.

2019Bulletin of experimental biology and medicine

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.

Animal studyratPMID 31625062

The effects of a peptide anxiolytic Selank synthesized on the basis of the endogenous peptide tuftsin on memory impairment and content of brain-derived neurotrophic factor (BDNF) in brain structures were analyzed in outbred rats receiving 10% ethanol as the only source of fluid for 30 weeks. In the object recognition test, Selank (0.3 mg/kg a day, 7 days, intraperitoneally) produced a cognitive-stimulating effect in 9 months rats not exposed to ethanol (p<0.05) and prevented the formation of ethanol-induced memory and attention disturbances (p<0.01) developing during alcohol withdrawal. In ex vivo experiments, Selank prevented ethanol-induced increase in BDNF content in the hippocampus and frontal cortex (p<0.05). These results indicate positive effects of the tuftsin analogue on age-related memory disturbances associated with chronic alcohol intoxication and confirm the involvement of the neurotrophin mechanism related to BDNF production into the effect of Selank.

2016Eksperimental'naia i klinicheskaia farmakologiia

[COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.].

Animal studymousePMID 29787664

Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 &#x3bc;g/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring the binding of markers to NMDA and GABA receptors of brain. The anxiolytic and nootropic efficiency of selank administered via both routes was observed only in BALB/c mice, which were characterized by initially reduced exploratory activity and higher levels of anxiety as compared to C57BL/6 mice. In BALB/c mice, i.p. selank increased the number of [G-(3)H]SR 95531 binding sites with GABA-receptors in the frontal cortex by 38%, without change in binding to NMDA receptors in the hippocampus. On the contrary, i.n. selank led to an increase in the density of [G-(3)H]MK-801 binding sites by 23% with no effect on GABA receptors. It is suggested that the differences in pharmacological spectra observed for the two routes of selank administration are determined by specific features of drug pharmacokinetics and biotransformation as well as by the dynamics of formation of the anxiolytic and nootropic effects of selank.

2001Bulletin of experimental biology and medicine

The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.

Human (observational)humanPMID 11550013

Examination of patients with various forms of anxiety and phobic disorders (according to DSM-4 criteria) demonstrated a considerable shortening of enkephalin half-life and reduced total enkephalinase activity in the blood during generalized anxiety, but not during panic disorders and agoraphobia. This was probably related to low blood concentration of endogenous inhibitors of enkephalin-degrading enzymes in patients with generalized anxiety disorders. Heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), which attenuates behavioral anxiety reactions and does not cause side effects typical of most anxiolytics, dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin (IC50 15 microM). Selank was more potent than peptidase inhibitors bacitracin and puromycin in inhibiting enkephalinases. These results suggest that high efficiency of Selank in the therapy of anxiety and phobic disorders, including generalized anxiety, is due to its ability to inhibit enkephalin hydrolysis.

2010Eksperimental'naia i klinicheskaia farmakologiia

[Experimental optimization of learning and memory processes by selank].

Animal studyratPMID 20919548

The effect of selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), which is a synthetic derivative of the endogenous tetrapeptide tuftsin (stable with respect to tissue peptidases), on the learning and memory processes and metabolism of serotonin (5-HT) have been experimentally studied on Wistar rats. The animals were trained with food reward in 30 trials per day. Selank (300 microg/kg) or saline were injected after the 10th trial. Elaboration of conditioned reflex with food reward was continued 30 min later. Retention was tested 24 h, 7 and 30 days after treatment. A single injection of selank activated the metabolism of 5-HT in the hypothalamus and caudal brain stem for 30 min to 2 h. It was established that selank induces an increase in memory trace stability during 30 days. These findings provide direct evidence that selank, when injected during consolidation phase, can enhance memory storage processes. Nootrope activity of the selank is probably caused by its obvious effect on the level of serotonin and its metabolite in the brain.

2005Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova

[Effect of new synthetic anxiolytic selank on gastric wall blood flow and mesenteryc lymphatic vessels contractility in anesthetized rats].

Animal studyratPMID 15835541

The influence of a new heptapeptide Selank on microcirculation in anesthetized white rats was investigated. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a new synthetic anxiolytic which exerts obvious antiulcerogenic action and promotes healing of experimental ulcers. Action of the peptide on gastric blood flow in the stomach by using the method ofhydrogenic clearance and Selank action on mesenteric lymphatic contractility by microscopical observation in situ, were studied. Selank fail to influence basal gastric blood flow but it can normalize blood flow reduced by indomethacin. The study of dose-depended of Selank effect on lymphatic vessels contractility showed that its low concentration (10(-12)--10(-14) M) enhanced amplitude and increase frequency of lymphatic vessel contractions which indicates an enhancement of lymphatic flow. The high doses of peptide (10(-6)--10(-10) M) also augmented the contraction amplitude but decreased its frequency. The maintenance of adequate blood flow and lymphatic vessel contractility can be one of the mechanisms of the Selank antiulcerogenic properties.

2014Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].

Human (observational)humanPMID 25176261

Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a week after last receiving the peptide. Selank had a positive impact on the quality of life of the patients. Conclusion. The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders.

2008Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].

Lab / cellsin vitroPMID 18577961

The purpose of this article was to study the immunotropic effects of the new neurotrophic heptapeptide selank. The experiments in vitro revealed that the drug in concentration 10-7 M completely suppressed gene expression by peripheral blood IL-6 of patients with depression but not of the healthy controls. At the same time, the significant increase (p<0,05) of IL-6 concentration was observed in the cell culture of peripheral blood of patients in the presence of selank. The changes of the Th1/Th2 cytokine balance in vivo were found in the serum of patients with generalized anxiety disorder and neurasthenia who received Selank during 14 days. The dynamics of these changes had the significant inverse correlation dependence. The cytokine regulating effects revealed in the study suggest that selank can be used as a novel immunomodulator in patients with anxiety-asthenic disorders. Additionally, the adaptogenic properties of selank may be beneficial to its use in elderly people and people exposed to environmental stressors for the prevention of infectious diseases.

2005Bulletin of experimental biology and medicine

Seasonal effects of Selank on the behavior of hibernating animals.

We studied the seasonal effects of peptide preparation Selank on orientation and exploratory activity in 36 arctic ground squirrels Citellus undulatus in the open-field and hole-board tests. Selank most significantly increased behavioral activity of hibernating animals in the spring and fall. The test peptide had no effect on locomotor activity of animals. The selective stimulatory effect of Selank on exploratory behavior of hibernating animals was season-dependent. The maximum effect was observed under conditions of seasonal depression-like state.

2013Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova

[Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank].

Animal studyratPMID 24450168

The effect of single and course administration of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) in the dose 200 microg/kg on the rat hippocampus transcriptional profile were studied using cDNA microarray technology. It was shown that mRNA levels of 36 genes changed more than 2-fold after a single intranasal Selank administration, and 20 genes--after course administration. It should be noted that most of them encode proteins associated with the plasma membrane (including transmembrane proteins). This suggests that Selank is able to regulate ion homeostasis of hippocampal cells and thereby modulate different ion-dependent processes, which include the processes of learning and memory formation.

2006Bulletin of experimental biology and medicine

Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system.

Animal studyratPMID 17415472

Peptide anxiolytic selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) applied intraperitoneally in doses of 0.01, 0.1, 1.0, and 10.0 mg/kg to mice reduces behavioral manifestations of dopaminergic system induced by apomorphine in the verticalization test. This effect was comparable to that of atypical antipsychotic olanzapine in near-therapeutic doses (0.1 and 1.0 mg/kg, intraperitoneally) and was blocked with nonselective opioid receptor antagonist naloxone (10 mg/kg, intraperitoneally). Radioreceptor assay showed that selank did not displace nonselective D2-dopamine receptor antagonist (3)H-spiperone (EC50>100 microM) and delta- and micro-opioid receptor ligand 3H-DADLE (EC50>40 microM) from specific binding sites on rat brain membranes. It is hypothesized that the revealed behavioral effect of selank is mediated by its modulating effect on the endogenous opioid system and specifically, by its effect on activity of enkephalin-degrading enzymes.

2006Izvestiia Akademii nauk. Seriia biologicheskaia

[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].

Experimental and theoretical demonstration of different effect of certain regulatory peptides (RPs) on blood coagulation is available. The problem of the role of RPs in hemostatic processes becomes particularly significant since, first, the peptides are widespread in nature both in animal and plant tissues, second, there is a relationship between the peptide structure and function and, third, both natural and synthetic peptides are used in practical medicine to correct functions of some factors of the hemostatic system. Many peptide inhibitors of the primary and plasma hemostasis potentiating anticoagulant effects in the body have been described.

2007Bulletin of experimental biology and medicine

Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny.

Animal studyratPMID 18683497

Effects of selank on learning, memory, and attention to sensory stimuli of different modality were studied in adult Wistar rats treated with 6-hydroxydopamine (neurotoxin selectively damaging catecholaminergic neurons and their terminals) during the first 3 days of life. Selank (300 microg/kg) restored cognitive processes disordered by chronic artificial inhibition of the cerebral catecholaminergic system.

2016Bulletin of experimental biology and medicine

Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice.

Animal studymousePMID 27878720

The effect of non-benzodiazepine anxiolytics on the ethanol-induced hyperlocomotion and behavioral sensitization was assessed in male DBA/2 mice. Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally), similar to the nonselective opiate receptor blocker naloxone (1.0 mg/kg, intraperitoneally), prevented the development of ethanol-induced (2.0 g/kg intraperitoneally) hyperlocomotion, in contrast to &#x3c3;1-receptors agonist Afobazole (1.0 mg/kg, intraperitoneally) that did not inhibit ethanol-induced behavioral stimulation. Single dose of Selank significantly blocked manifestation of motor sensitization without affecting its formation. These findings suggest that Selank can modulate the motivational effects of ethanol.

2002Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova

[Optimizing action of synthetic peptide Selank on active avoidance conditioning test in rats].

Animal studyratPMID 12449836

The action of a synthetic peptide Selank on learning and memory in active avoidance conditioning test was studied in rats with initially low learning ability and normal animals. The peptide was administered repeatedly 15 min prior the training session (4 days). The effect of Selank (300 micrograms/kg) was compared to that of Pyracetam (400 mg/kg). Selank was found to significantly improve learning in rats with low level ability even after a single administration on the first day of training session. The effect progressively increased with repeated Selank treatment: the total numbers of reactions and correct reactions increased, and the number of errors decreased (p < 0.05). In normal rats, the effect was maximal on the third day of treatment and training, i.e., after the completed initial consolidation. Some distinguishing features were revealed in the dynamics of activatory effects of Selank and Pyracetam. These data together with the evidence for ansiolytic effect of Selank show that this drug is promising for optimization of mnestic functions under conditions of high emotional stress.

2009Eksperimental'naia i klinicheskaia farmakologiia

[Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA].

Animal studyratPMID 19803361

Effects of the peptide drugs selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and tuftsin (Thr-Lys-Pro-Arg) on the metabolism of serotonin (5-hydroxytryptamine, 5-HT) in the brain of Wistar rats preliminarily treated with the 5-HT-synthesis inhibitor p-chlorophenylalanine (PCPA, 320 mg/kg, i.p., 4 days before experiment) have been studied on a group of 87 matured rats. It is established that selank enhances the 5-HT metabolism in the brain stem 30 min after injection to animals pretreated with PCPA. In contrast to selank, tuftsin induced no changes in the 5-HT metabolism in the brain stem and decreased it in the neocortex on the same time scale. The data obtained suggest that the peptide drug selank can be used for the correction of disturbances induced by a decrease in 5-HT metabolism.

2008Eksperimental'naia i klinicheskaia farmakologiia

[Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study].

Animal studymousePMID 19093364

The effect of heptapeptide selank on the content of neurotransmitter monoamines and its metabolites in the brain structures of BALB/C and C57Bl/6 line mice under conditions of the open-field test were studied. Significant interstrain differences in the content of norepinephrine (NE), dopamine (DA), serotonin (5-HT) as well as in the levels of their metabolites in hippocampus, hypothalamus, striatum and frontal cortex of C57Bl/6 and BALB/C mice were demonstrated. In particular, the content of 5-HT and its metabolite 5-oxyindolacetic acid (5-HIAA) in hippocampus of BALB/C mice (with passive stress response) was higher than in the same structure of C57Bl/6 (stress-susceptible) animals. The injection of selank (0.3 mg/kg) led to an increase in the NE level in the hypothalamus of both mice strains. At the same time, selank produced opposite effects on the content of DA metabolites: the concentrations of dioxyphenylacetic (DOPAC) and homovanillic (HVA) acids were found to increase in frontal cortex and hippocampus of C57Bl/6 mice, while the same parameters in BALB/C mice were demonstrated to decrease. Selank induced a decrease in 5-HT and 5-HIAA levels in the hippocampus of BALB/C mice, but did not affect these parameters in C57Bl/6 animals. The obtained results are indicative of selectivity of the anxiolytic effects of selank.

2017Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections

Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.

Animal studyratPMID 28702721

Parkinson's disease (PD) is the second most common severe neurodegenerative disorder that is characterized by progressive degeneration of dopaminergic neurons (DA neurons) in the substantia nigra pars compacta (SNpc) region of the brain. In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism. It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals. At the same time, Selank decreased level of anxiety of rats with toxic damage of DA neurons in elevated cross shaped maze. Previously such effects of Selank were revealed in healthy rodents (rats and mice) with different models of psycho-emotional stress. Therefore, toxic damage of substantia nigra does not affect the response of the rat organism on this peptide.

2008Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].

Human (observational)humanPMID 18454096

Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam (32 patients). Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI). Enkephalin activity in the blood serum was measured as well. The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients with GAD and neurasthenia had the decreased level of tau(1/2) leu-enkephalin which was correlated with disease duration, severity of symptoms related to anxiety and asthenia and autonomic disorders. The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.

Quick links (PubMed)

  • PMID 41490200 2026 · Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Futu
  • PMID 28745220 2017 · Tuftsin - Properties and Analogs.
  • PMID 36322304 2022 · Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphi
  • PMID 31243679 2019 · Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foo
  • PMID 24291245 2014 · The temporary dynamics of inflammation-related genes expression under tu
  • PMID 28293190 2017 · GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in
  • PMID 32342318 2020 · Functional Connectomic Approach to Studying Selank and Semax Effects.
  • PMID 26924987 2016 · Selank Administration Affects the Expression of Some Genes Involved in G
  • PMID 30255741 2018 · Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank
  • PMID 26356395 2015 · [Optimization of the treatment of anxiety disorders with selank].
  • PMID 28280289 2017 · Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Un
  • PMID 32621722 2021 · The Influence of Selank on the Level of Cytokines Under the Conditions o
  • PMID 32651826 2020 · Morphological Changes in the Large Intestine of Rats Subjected to Chroni
  • PMID 31236882 2019 · State of Colon Microbiota in Rats during Chronic Restraint Stress and Se
  • PMID 14552529 2003 · The optimizing action of the synthetic peptide Selank on a conditioned a
  • PMID 18661785 2008 · [Effects of heptapeptide selank on genetically-based and situation-provo
  • PMID 21609736 2011 · Expression of inflammation-related genes in mouse spleen under tuftsin a
  • PMID 28361410 2017 · Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1
  • PMID 28853100 2017 · Effect of Selank on Functional State of Rat Hepatocytes under Conditions
  • PMID 31625062 2019 · Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Me
  • PMID 29787664 2016 · [COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTR
  • PMID 11550013 2001 · The inhibitory effect of Selank on enkephalin-degrading enzymes as a pos
  • PMID 20919548 2010 · [Experimental optimization of learning and memory processes by selank].
  • PMID 15508574 2004 · A new property of the synthetic anxiolytic Selank and its derivatives.
  • PMID 15835541 2005 · [Effect of new synthetic anxiolytic selank on gastric wall blood flow an
  • PMID 25176261 2014 · [A comparison of the anxiolytic effect and tolerability of selank and ph
  • PMID 18577961 2008 · [Immunomodulatory effects of selank in patients with anxiety-asthenic di
  • PMID 16848230 2005 · Seasonal effects of Selank on the behavior of hibernating animals.
  • PMID 24450168 2013 · [Transcriptome alteration in hippocampus under the treatment of tuftsin
  • PMID 17415472 2006 · Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-in
  • PMID 16634437 2006 · [Comparison of anticoagulant effects of regulatory proline-containing ol
  • PMID 18683497 2007 · Effect of selank on cognitive processes after damage inflicted to the ce
  • PMID 25371249 2014 · The influence of Selank on the parameters of the hemostasis system, lipi
  • PMID 27878720 2016 · Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Beh
  • PMID 12449836 2002 · [Optimizing action of synthetic peptide Selank on active avoidance condi
  • PMID 19803361 2009 · [Comparison of the effects of selank and tuftsin on the metabolism of se
  • PMID 19093364 2008 · [Effects of heptapeptide selank on the content of monoamines and their m
  • PMID 20506839 2010 · Antiviral properties of structural fragments of the peptide Selank.
  • PMID 28702721 2017 · Peptides semax and selank affect the behavior of rats with 6-OHDA induce
  • PMID 18454096 2008 · [Efficacy and possible mechanisms of action of a new peptide anxiolytic